Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”
Drugs in R&D · 2026-03 · 26 (1) · 35-37
DOI: 10.1007/s40268-026-00536-x ↗Kurz gefasst
Leserbrief in der Zeitschrift Drugs in R&D, online erschienen am 28.03.2026. Verfasst von Imtiaz A Samjoo. Beteiligte Einrichtung: EVERSANA, 113-3228 South Service Road, Burlington, ON, L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- EVERSANA, 113-3228 South Service Road, Burlington, ON, L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com.
Zitieren
APA
Samjoo, I. A. (2026). Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”. Drugs in R&D, 26(1), 35-37. https://doi.org/10.1007/s40268-026-00536-x
Vancouver
Samjoo IA. Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”. Drugs in R&D. 2026;26(1):35-37. doi:10.1007/s40268-026-00536-x
BibTeX
@article{Samjoo2026,
author = {Samjoo, Imtiaz A},
title = {Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”},
journal = {Drugs in R&D},
year = {2026},
volume = {26},
number = {1},
pages = {35--37},
doi = {10.1007/s40268-026-00536-x}
}
EUVIMED